Innate Pharma SA (IPHA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.89

From 52W high−25.20%

Volume91437.00

Market cap$212.23M

P/E (TTM)—

P/S (TTM)170.6x

Div yield—

Key dataSep 18, 2026

Open

$1.89

From 52W high

−25.20%

Volume

91437.00

Market cap

$212.23M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.5x

P/E (TTM)

—

RSI (14)

42.9

MomentumView details →

1D Return

−0.52%

YTD Return

+7.14%

SummaryUpdated Jun 1, 2026

Innate Pharma S.A. (NASDAQ:IPHA) is a French biotechnology company founded in 1999 and headquartered in Marseille, France. The company went public on NASDAQ in October 2019. Innate Pharma specializes in discovering, developing, and commercializing therapeutic antibodies primarily focused on oncology treatments, with a particular emphasis on leveraging the immune system to fight cancer through innovative approaches including natural killer (NK) cell engagers and antibody-drug conjugates.

Ask drillr about Innate Pharma SA →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.5x

EV/Sales

170.5x

P/S (TTM)

170.6x

P/B (TTM)

−4.6x

ProfitabilityView details →

Gross Margin

1701.86%

Net Margin

−4383.51%

EBITDA Margin

−4848.49%

ROE (TTM)

117.34%

ROA (TTM)

−136.88%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

−78.90%

EPS YoY

+7.27%

FCF YoY

−1.72%

Revenue CAGR 3Y

−63.58%

EPS CAGR 3Y

+13.11%

EBITDA YoY

−13.24%

MomentumView details →

1D Return

−0.52%

YTD Return

+7.14%

1Y Return

+0.27%

RSI (14)

42.9

vs 50D SMA

−4.75%

vs 200D SMA

+7.18%

Capital & dividendView details →

Debt/Equity

−0.27x

Current Ratio

0.60x

Quick Ratio

0.60x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.24

EPS Surprise

18.12%

Beats (12Q)

2/12

Next Q EPS Est

−$0.28

Avg Surprise (4Q)

−10.33%

Rev Surprise

2.38%

Financials snapshotView financials →

Revenue (TTM)

6.22M

Net Income (TTM)

−93.57M

Op. CF (TTM)

−88.69M

Latest newsMore news →

Innate Pharma's strategic partnership with Sobi to license lacutamab in T-cell lymphoma became effective after antitrust waiting periods expired and closing conditions were met, triggering a USD 75 million payment.4d ago

Innate Pharma S.A. announced an equity raise of EUR 30 million.37d ago

Similar companies

Eledon Pharmaceuticals, Inc.ELDN Alector, Inc.ALEC Protara Therapeutics, Inc.TARA Veraxa Biotech Holding AGVRXA Coherus Oncology, Inc.CHRS NervGen Pharma Corp. Common stockNGEN Find similar companies →

Latest newsMore news →